Literature DB >> 9163836

Antibiotic selection in the treatment of endophthalmitis: the significance of drug combinations and synergy.

D B Roth1, H W Flynn.   

Abstract

Emerging resistance of organisms to standard antibiotic therapy has forced clinicians to continually evaluate the best intraocular antibiotics for the treatment of endophthalmitis. Early diagnosis and appropriate treatment with intraocular antibiotics are important factors in the successful management of endophthalmitis. Although drug combinations are necessary to cover the full range of bacteria causing endophthalmitis, antimicrobial synergy is probably less important in endophthalmitis treatment because of the high intravitreal concentration of individual antibiotics achieved by intravitreal injection. In the treatment of bacterial endophthalmitis, the combination of intravitreal vancomycin (1 mg/0.1 cc) and ceftazidime (2.25 mg/ 0.1 cc) is a reasonable alternative to the combination vancomycin and amikacin (0.4 mg/ 0.1 cc).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163836     DOI: 10.1016/s0039-6257(97)00005-2

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  19 in total

1.  Endophthalmitis: antibacterial activity of precipitates of vancomycin and ceftazidime.

Authors:  Kuan-Jen Chen; Tun-Lu Chen; Chi-Chun Lai; Ming-Hui Sun
Journal:  J Clin Microbiol       Date:  2008-06       Impact factor: 5.948

2.  Severe bacterial endophthalmitis: towards improving clinical outcomes.

Authors:  Billy D Novosad; Michelle C Callegan
Journal:  Expert Rev Ophthalmol       Date:  2010-10

3.  Emerging Worldwide Antimicrobial Resistance, Antibiotic Stewardship and Alternative Intravitreal Agents for the Treatment of Endophthalmitis.

Authors:  Nidhi Relhan; Avinash Pathengay; Stephen G Schwartz; Harry W Flynn
Journal:  Retina       Date:  2017-05       Impact factor: 4.256

Review 4.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

5.  Therapeutic Effects of Intravitreously Administered Bacteriophage in a Mouse Model of Endophthalmitis Caused by Vancomycin-Sensitive or -Resistant Enterococcus faecalis.

Authors:  Tatsuma Kishimoto; Waka Ishida; Ken Fukuda; Isana Nakajima; Takashi Suzuki; Jumpei Uchiyama; Shigenobu Matsuzaki; Daisuke Todokoro; Masanori Daibata; Atsuki Fukushima
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

6.  Chronic postoperative Roseomonas endophthalmitis.

Authors:  Kuan-Jen Chen; Chi-Chun Lai; Ya-Hui Kuo; Wei-Chi Wu; Tun-Lu Chen
Journal:  J Clin Microbiol       Date:  2008-11-05       Impact factor: 5.948

7.  An in vitro study on the compatibility and precipitation of a combination of ciprofloxacin and vancomycin in human vitreous.

Authors:  M Hui; A K H Kwok; C P Pang; S W Cheung; R C Y Chan; D S C Lam; A F B Cheng
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

8.  Isolates and antibiotic susceptibilities of endophthalmitis in postcataract surgery: a 12-year review of culture-proven cases.

Authors:  Yu Ti Teng; Mei Ching Teng; Hsi Kung Kuo; Po Chiung Fang; Pei Chang Wu; Chih Hsin Chen; Ming Tse Kuo; I Hui Yang; Yung Jen Chen
Journal:  Int Ophthalmol       Date:  2016-07-15       Impact factor: 2.031

9.  Combination therapies in ophthalmology: implications for intravitreal delivery.

Authors:  Gholam A Peyman; Kamran Hosseini
Journal:  J Ophthalmic Vis Res       Date:  2011-01

10.  Integrative metabolomics and transcriptomics identifies itaconate as an adjunct therapy to treat ocular bacterial infection.

Authors:  Sukhvinder Singh; Pawan Kumar Singh; Alokkumar Jha; Poonam Naik; Joveeta Joseph; Shailendra Giri; Ashok Kumar
Journal:  Cell Rep Med       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.